Serum gamma-seminoprotein determination in prostatic cancer. 1991

J Shimazaki, and S Akimoto, and K Akakura, and T Yoshiki, and O Yoshida, and K Okada, and K Matsuoka, and S Noda, and K Eto
Department of Urology, School of Medicine, Chiba University.

Serum gamma-seminoprotein (gamma-Sm) was evaluated as a new marker for prostatic cancer in comparison with prostatic acid phosphatase (PAP). The sensitivity of gamma-Sm and PAP for untreated prostatic cancer was 81% and 67%, respectively. gamma-Sm showed a higher positive rate over all stages than in benign prostatic hypertrophy (BPH). There was no correlation between gamma-Sm and PAP in prostatic cancer. Improved sensitivity was obtained by simultaneous measurement of gamma-Sm and PAP. Specificity of gamma-Sm and PAP for BPH was 87% and 90%, respectively. gamma-Sm normalized after endocrine therapy for stage D2 more often than did PAP. These results indicate that gamma-Sm is another useful marker to evaluate prostatic cancer.

UI MeSH Term Description Entries
D008297 Male Males
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000135 Acid Phosphatase An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2. Acid beta-Glycerophosphatase,Acid beta Glycerophosphatase
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D029584 Prostatic Secretory Proteins Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94. Proteins, Prostatic Secretory,Secretory Proteins, Prostatic

Related Publications

J Shimazaki, and S Akimoto, and K Akakura, and T Yoshiki, and O Yoshida, and K Okada, and K Matsuoka, and S Noda, and K Eto
January 1985, Hinyokika kiyo. Acta urologica Japonica,
J Shimazaki, and S Akimoto, and K Akakura, and T Yoshiki, and O Yoshida, and K Okada, and K Matsuoka, and S Noda, and K Eto
June 1985, Hinyokika kiyo. Acta urologica Japonica,
J Shimazaki, and S Akimoto, and K Akakura, and T Yoshiki, and O Yoshida, and K Okada, and K Matsuoka, and S Noda, and K Eto
March 1989, Hinyokika kiyo. Acta urologica Japonica,
J Shimazaki, and S Akimoto, and K Akakura, and T Yoshiki, and O Yoshida, and K Okada, and K Matsuoka, and S Noda, and K Eto
December 1987, Hinyokika kiyo. Acta urologica Japonica,
J Shimazaki, and S Akimoto, and K Akakura, and T Yoshiki, and O Yoshida, and K Okada, and K Matsuoka, and S Noda, and K Eto
January 1992, Urologia internationalis,
J Shimazaki, and S Akimoto, and K Akakura, and T Yoshiki, and O Yoshida, and K Okada, and K Matsuoka, and S Noda, and K Eto
August 1983, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
J Shimazaki, and S Akimoto, and K Akakura, and T Yoshiki, and O Yoshida, and K Okada, and K Matsuoka, and S Noda, and K Eto
September 1991, British journal of urology,
J Shimazaki, and S Akimoto, and K Akakura, and T Yoshiki, and O Yoshida, and K Okada, and K Matsuoka, and S Noda, and K Eto
December 1991, British journal of urology,
J Shimazaki, and S Akimoto, and K Akakura, and T Yoshiki, and O Yoshida, and K Okada, and K Matsuoka, and S Noda, and K Eto
December 1987, Hinyokika kiyo. Acta urologica Japonica,
J Shimazaki, and S Akimoto, and K Akakura, and T Yoshiki, and O Yoshida, and K Okada, and K Matsuoka, and S Noda, and K Eto
December 1985, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
Copied contents to your clipboard!